MA52764A - Anticorps anti-siglec-7 et leurs méthodes d'utilisation - Google Patents

Anticorps anti-siglec-7 et leurs méthodes d'utilisation

Info

Publication number
MA52764A
MA52764A MA052764A MA52764A MA52764A MA 52764 A MA52764 A MA 52764A MA 052764 A MA052764 A MA 052764A MA 52764 A MA52764 A MA 52764A MA 52764 A MA52764 A MA 52764A
Authority
MA
Morocco
Prior art keywords
siglec
antibodies
methods
Prior art date
Application number
MA052764A
Other languages
English (en)
Inventor
Patricia Culp
Wei-Hsien Ho
Helen Lam
Seung-Joo Lee
Arnon Rosenthal
Original Assignee
Alector Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alector Llc filed Critical Alector Llc
Publication of MA52764A publication Critical patent/MA52764A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA052764A 2018-06-08 2019-06-07 Anticorps anti-siglec-7 et leurs méthodes d'utilisation MA52764A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862682439P 2018-06-08 2018-06-08

Publications (1)

Publication Number Publication Date
MA52764A true MA52764A (fr) 2021-04-28

Family

ID=67003745

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052764A MA52764A (fr) 2018-06-08 2019-06-07 Anticorps anti-siglec-7 et leurs méthodes d'utilisation

Country Status (13)

Country Link
US (1) US20210246204A1 (fr)
EP (1) EP3801767A1 (fr)
JP (1) JP7382970B2 (fr)
KR (1) KR20210030341A (fr)
CN (1) CN112512638A (fr)
AU (1) AU2019282778A1 (fr)
BR (1) BR112020024919A2 (fr)
CA (1) CA3100626A1 (fr)
EA (1) EA202092595A1 (fr)
IL (1) IL279227A (fr)
MA (1) MA52764A (fr)
MX (1) MX2020013172A (fr)
WO (1) WO2019236965A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2996059A1 (fr) 2015-08-28 2017-03-09 Alector Llc Anticorps anti-siglec-7 et leurs methodes d'utilisation
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
DE3850542T2 (de) 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991000360A1 (fr) 1989-06-29 1991-01-10 Medarex, Inc. Reactifs bispecifiques pour le traitement du sida
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP0463151B1 (fr) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation d'anticorps xenogeniques
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE204902T1 (de) 1990-06-29 2001-09-15 Large Scale Biology Corp Melaninproduktion durch transformierte mikroorganismen
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0861893A3 (fr) 1991-09-19 1999-11-10 Genentech, Inc. Expression de haut niveau d'immunoglobulines
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
EP0625200B1 (fr) 1992-02-06 2005-05-11 Chiron Corporation Proteine de liaison biosynthetique pour marqueur de cancer
EP0656064B1 (fr) 1992-08-17 1997-03-05 Genentech, Inc. Immunoadhesines bispecifiques
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP1978033A3 (fr) 1995-04-27 2008-12-24 Amgen Fremont Inc. Anticorps humains dérivés à partir de xénosouris immunisée
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU7378096A (en) 1995-09-28 1997-04-17 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
EP1500329B1 (fr) 1996-12-03 2012-03-21 Amgen Fremont Inc. Les anticorps humains qui lient en particulier l'alpha de TNF humain
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
JP4460155B2 (ja) 1997-12-05 2010-05-12 ザ・スクリプス・リサーチ・インステイチユート マウス抗体のヒト化
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
AU782626B2 (en) 1999-10-04 2005-08-18 Medicago Inc. Method for regulating transcription of foreign genes
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CA2502413A1 (fr) 2002-11-01 2004-05-21 The Regents Of The University Of Colorado, A Body Corporate Analyse quantitative d'isoformes de proteines utilisant la spectrometrie de masse a temps de vol par desorption/ionisation laser assistee par matrice
US20080181888A1 (en) 2004-12-31 2008-07-31 Ambrose Christine M Polypeptides That Bind Br3 and Uses Thereof
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
AU2007225044C1 (en) 2006-03-15 2018-03-29 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
US9885711B2 (en) 2009-09-25 2018-02-06 Xoma Technology Ltd. Screening methods
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
DK3191517T3 (da) * 2014-09-10 2021-01-25 Innate Pharma Krydsreaktive siglec-antistoffer
CA2996059A1 (fr) * 2015-08-28 2017-03-09 Alector Llc Anticorps anti-siglec-7 et leurs methodes d'utilisation
AU2017290554B2 (en) * 2016-07-01 2020-10-08 The Board Of Trustees Of The Leland Stanford Junior University Conjugates for targeted cell surface editing
CN106831989A (zh) * 2017-01-04 2017-06-13 中国人民解放军***军事医学研究所 人源抗唾液酸结合免疫球蛋白样凝集素‑7的抗体IgG及其应用
CA3087968A1 (fr) * 2018-01-11 2019-07-18 Allakos, Inc. Anticorps anti-siglec-7 ayant une fonction effectrice reduite

Also Published As

Publication number Publication date
KR20210030341A (ko) 2021-03-17
EA202092595A1 (ru) 2021-04-12
CA3100626A1 (fr) 2019-12-12
US20210246204A1 (en) 2021-08-12
JP7382970B2 (ja) 2023-11-17
JP2021526794A (ja) 2021-10-11
WO2019236965A1 (fr) 2019-12-12
AU2019282778A1 (en) 2020-12-10
IL279227A (en) 2021-01-31
BR112020024919A2 (pt) 2021-03-09
EP3801767A1 (fr) 2021-04-14
CN112512638A (zh) 2021-03-16
MX2020013172A (es) 2021-03-29

Similar Documents

Publication Publication Date Title
MA50957A (fr) Anticorps anti-tigit et leurs méthodes d'utilisation
MA45123A (fr) Anticorps anti-tim-3 et leurs méthodes d'utilisation
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d'utilisation
MA43387A (fr) Anticorps anti-gitr et leurs méthodes d'utilisation
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
MA50359A (fr) Anticorps anti-cd38 et procédés d'utilisation
MA52014A (fr) Anticorps anti-klk5 et méthodes d'utilisation
MA49288A (fr) Reactifs particulaires oligomères et leurs méthodes d'utilisation
MA42243A (fr) Anticorps de facteur xi et méthodes d'utilisation
MA48579A (fr) Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
MA50956A (fr) Anticorps anti-cd137 et procédés d'utilisation correspondants
MA49950A (fr) Anticorps anti-b7-h4 et leurs procédés d'utilisation
MA52459A (fr) Anticorps se liant spécifiquement à pd-1 et leurs méthodes d'utilisation
MA42446A (fr) Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
MA48595A (fr) Anticorps anti-tau et leurs méthodes d'utilisation
MA56165A (fr) Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
MA47499A (fr) Anticorps anti-tau et leurs procédés d'utilisation
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
MA50958A (fr) Anticorps anti-apoc3 et leurs méthodes d'utilisation
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
MA43385A (fr) Nouveaux anticorps anti-claudine et méthodes d'utilisation
MA44955A (fr) Anticorps anti-tau et leurs méthodes d'utilisation
MA53492A (fr) Anticorps anti-cd33 et leurs méthodes d'utilisation
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation